2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-isochroman-1-ylmethyl-benzamide | 531507-15-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-isochroman-1-ylmethyl-benzamide
• 英文别名: 2-chloro-N-(3,4-dihydro-1H-isochromen-1-ylmethyl)-5-(3,5-dioxo-1,2,4-triazin-2-yl)benzamide
• CAS: 531507-15-0
• 化学式: C₂₀H₁₇ClN₄O₄
• 分子量: 412.832
• InChiKey: HCAAYBGAMGJORR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Benzamide, heteroarylamide and reverse amides
  申请人：Pfizer Inc.

  公开号：US20030186981A1

  公开（公告）日：2003-10-02

  The present invention relates to novel to P2X 7 inhibitors of formula I 1 and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are potent inhibitors of P2X 7 and as such are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及一种新的P2X7抑制剂的I1式，以及其制备方法、制备中间体、含有它们的药物组合物，以及它们在治疗中的应用。本发明的活性化合物是P2X7的有效抑制剂，因此在治疗炎症、骨关节炎、类风湿关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病中具有用途。
• BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS
  申请人：Pfizer Products Inc.

  公开号：EP1448535A1

  公开（公告）日：2004-08-25
• US7214677B2
  申请人：——

  公开号：US7214677B2

  公开（公告）日：2007-05-08
• US7235549B2
  申请人：——

  公开号：US7235549B2

  公开（公告）日：2007-06-26
• [EN] BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] BENZAMIDE ET HETEROARYLAMIDE UTILISES COMME ANTAGONISTES DU RECEPTEUR P2X7
  申请人：PFIZER PROD INC

  公开号：WO2003042191A1

  公开（公告）日：2003-05-22

  The present invention relates to novel to P2X7 inhibitors of formula (I) and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are potent inhibitors of P2X7 and as such are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.